[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Janssen Korea, Ltd., Korea\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100649698","a-study-of-radical-cystectomy-in-participants-with-non-muscle-invasive-bladder-cancer-nmibc-and-muscle-invasive-bladder-cancer-mibc-in-korea-100649698",false,"NCT07735793","A Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in Korea","Clinical and Economic Outcomes of Radical Cystectomy Among NMIBC and MIBC Patients: Nationwide Claims-Based Study in Korea","BC RC DB","Inclusion criteria:\n\n* Participants newly diagnosed with bladder cancer (BC) (International statistical classification of diseases and related health problems, 10th revision \\[ICD-10\\] codes of malignant neoplasm of the bladder \\[C67\\] or carcinoma in-situ of bladder \\[D090\\] and cancer-specific insurance code of Korean national health insurance service \\[V193\\]) between September 1 2015 and August 31 2023\n* Having two outpatients or one inpatient visit anytime in the study period for BC\n\nExclusion criteria:\n\n* Participants with a history of BC diagnosis or cystectomy during the pre-index period\n* Participants with prior primary malignancy (ICD-10 codes) that was under active treatment or follow-up during the pre-index period\n* Participants with evidence of metastatic disease at the index date, defined as: a. Having secondary malignancy codes (ICD-10 codes), or b. Having received systemic chemotherapy for BC within 6 months of the initial transurethral resection of the bladder tumor (TURBT)","ALL","19 Years",{"count":20,"type":21},1,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess participant's overall well-being and the extent to which medical services are used by participants with non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) who have undergone radical cystectomy (surgical procedure to remove entire urinary bladder). NMIBC is a type of bladder cancer in which cancer is confined to innermost lining of the bladder and MIBC is a type of bladder cancer in which cancer has grown deep into the thick muscle of the bladder.",[25],"Urinary Bladder Neoplasms","NOT_YET_RECRUITING","2026-07-24",{"date":29,"type":30},"2026-07-30","ACTUAL",{"date":32,"type":21},"2026-07-27",{"date":34,"type":21},"2026-11-23",{"name":36,"class":37},"Janssen Korea, Ltd., Korea","INDUSTRY",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":20},"100632981","a-database-study-of-disease-treatment-patterns-and-healthcare-use-in-children-with-inflammatory-bowel-diseases-in-korea-100632981","NCT07520747","A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea","Epidemiology, Treatment Patterns, and Healthcare Resource Utilization in Pediatric Patients Under 18 Years of Age With Inflammatory Bowel Diseases in Korea: A Claims Database Study","Ped IBD Claims","Inclusion Criteria:\n\n* Participants with at least two outpatient or one inpatient diagnosis codes for the same disease type (either CD or UC) using international classification of diseases, tenth revision (ICD-10) codes (K50. X for CD and K51. X for UC) recorded as primary or the first secondary diagnosis, and the codes for rare and intractable disease registration program (V130 for CD, V131 for UC) during the index period\n* Participants who received at least one prescription for conventional pediatric inflammatory bowel disease (IBD)-related medications (for example, 5-aminosalicylic acids \\[5-ASAs\\], exclusive enteral nutrition \\[EENs\\], corticosteroids, immunomodulators, or biologic drugs) during the index period\n\nExclusion Criteria:\n\n\\- No specific exclusion criteria are defined in this study","17 Years",{"count":48,"type":21},8000,"The purpose of this study is:\n\n* to find out out the number of children who develop crohn's disease (CD) and ulcerative colitis (UC) each year and are living with the disease and to see how this differs by age groups.\n* to understand how children of different age groups are treated over time and how their treatment changes as they grow.\n* to assess how often children use healthcare services and how much this costs for different age groups over several years.\n\nCD and UC are long-term diseases that cause inflammation in intestine (part of digestive system) and develop ulcers.",[51],"Inflammatory Bowel Diseases","RECRUITING","2026-07-02",{"date":55,"type":30},"2026-07-06",{"date":57,"type":30},"2026-04-07",{"date":59,"type":21},"2026-07-31",{"name":36,"class":37},""]